Products - Allergies | Topic | NICE

Showing 8 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Palforzia for treating peanut allergy in children and young people (TA769)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Cryotherapy for Chronic Rhinitis
Status:
Awaiting development
Programme:
Interventional procedures guidance
Expected publication date:
27 September 2023
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
26 June 2024
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (ID3961)
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 TS ID 10510
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC